End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.07 CNY | +0.20% | -3.88% | -19.40% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company shows low valuation levels, with an enterprise value at 0.73 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.40% | 3.16B | C- | ||
-37.88% | 13.99B | B- | ||
-33.12% | 10.67B | B | ||
+12.54% | 6.29B | C | ||
-11.17% | 5.88B | C+ | ||
+75.00% | 4.96B | C | ||
-4.67% | 4.54B | D- | ||
-9.20% | 3.74B | B | ||
-12.15% | 2.85B | C- | ||
-12.99% | 2.53B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603233 Stock
- Ratings DaShenLin Pharmaceutical Group Co., Ltd.